It binds to the GHRH receptors in the anterior pituitary gland to stimulate the pulsatile secretion of growth hormone
Further trials are required in order to establish whether these dual GLP-1/glucagon agonists are superior to GLP-1 analogues, and whether the glucagon activity might reverse some of the improvements in glycaemia seen with GLP-1 analogues alone
Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements
Wegovy (semaglutide) is an FDA-approved medication that can be used for chronic weight management as part of a comprehensive chronic weight management program, along with diet and exercise
Cintra, P.A.F
Patients receiving this combination therapy benefit from regular follow-up appointments at our center to monitor treatment efficacy and safety
